Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients
- Conditions
- Chemotherapy-induced NeutropeniaCancer, Breast
- Interventions
- Registration Number
- NCT03246009
- Lead Sponsor
- Tianjin SinoBiotech Ltd.
- Brief Summary
The purpose of this study is to evaluate the tolerance and safety of the rHSA/GCSF in breast cancer patients with different doses and multiple injections.
To observe the pharmacokinetic characteristics of recombinant human serum albumin /granulocyte colony-stimulating factor fusion protein after single and multiple administration
- Detailed Description
This experiment adopts the method of multicenter, open, dose escalation study injection with recombinant human blood clean protein/granulocyte stimulating factor fusion protein after single and multiple doses of tolerance, security, and pharmacokinetic characteristics.
Breast cancer patients with reduced white blood cells after chemotherapy were selected as subjects of this study.
The three research doses that were to be incremented were 1.8 mg, 2.1mg and 2.4mg respectively, each of which was studied by single and multiple doses.
Single dose of medicine, dose-climbing study.Two doses of the drug, dose-climbing study
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
- Age 18-65.
- Diagnosed breast cancer，received chemotherapy.
- ECOG performance status 0 or 1.
- ANC≥1.5×10 9/L, PLT≥100×10 9/L. No bone marrow metastasis,blood coagulation function normally, no Hemorrhagic tendency.
- Leukocyte reduction occurred after chemotherapy,WBC≤3.0x109/L or ANC≤1.5x109/L.
- No obvious abnormal ecg examination.
- Cr，TBIL, AST, ALT≤1.5×ULN，no serious underlying disease.
- Signed informed consent.
- Chemotherapy within past 4 weeks.
- Uncontrolled inflammatory disease,axillary temperature≥38℃.
- Merging other malignant tumor.
- Pregnancy or nursing status.
- Participation in another clinical trial with and investigational product within 3 months prior to study entry.
- Severe diabetes mellitus, or poor blood sugar controller.
- Allergic disease or allergic constitution. History of protein allergy.
- History of drug addiction and alcoholism.
- Hematopoietic stem cell transplantation or organ transplantation.
- Received antibiotic treatment within 72 hours before chemotherapy.
- Long-term use of hormones or immunosuppressive agents.
- Severe mental or neurological disorders.
- Chronic disease of severe cardiac, kidney and liver.
- Other conditions that would be excluded from this study according to doctors'judgment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description single injection-1.8mg rHSA/GCSF rHSA/GCSF,injection,1.8mg,Single subcutaneous injection,Duration 1 day multiple injection-1.8mg rHSA/GCSF rHSA/GCSF,injection,1.8mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days. single injection-2.4mg rHSA/GCSF rHSA/GCSF,injection,2.4mg,Single subcutaneous injection,Duration 1 day single injection-2.1mg rHSA/GCSF rHSA/GCSF,injection,2.1mg,Single subcutaneous injection,Duration 1 day multiple injection-2.1mg rHSA/GCSF rHSA/GCSF,injection,2.1mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days. multiple injection-2.4mg rHSA/GCSF rHSA/GCSF,injection,2.4mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
- Primary Outcome Measures
Name Time Method Number of adverse events 14 days Number of participants with AE as a measure for safety and tolerability after single and multiple dose of rHSA/GCSF
- Secondary Outcome Measures
Name Time Method AUC 14 days AUC after single and multiple dose of rHSA/GCSF
Trial Locations
- Locations (1)
Chinese Academy of Medical Sciences Cancer Hospital
🇨🇳Beijing, Beijing, China